Bibliographical noteFunding Information:
Mark Katz received funding from the World Health Organization for this project.
The Wheeze Working Group comprised the following additional members: Mohammod Jobayer, Chisti Jobayer, Fahmida Chowdhury and Sandra Boamah. The authors are grateful for the support and helpful comments provided by the Brighton Collaboration Science Board (Jim Buttery, Barbara Law, Kathryn Edwards, Michael Gold, Miriam Sturkenboom, Steven Black, Hector Izurieta, Egeruan Babatunde Imoukhuede, Heidi Larson, Daniel Salmon) and Reference group (Shah Hossain, David Nalin, Dinesh Kumar, James Oleske, Sadhu Panda, S. Aneja, Merita Kucuku, R. Mandyam, Omala Wimalaratne, Q. Asma, B.Nisha, Reinaldo de Menezes Martins), as well as other experts consulted as part of the process. We also thank the Brighton Collaboration management team, particularly, Jorgen Bauwens, Simone Casagrande, Viviane Seeger for administrative and technical support.
Louis J. Bont reports his institution received grants from Abbvie and MedImmune, and consultancy fees from Janssen, Gilead, Okairos, Mabxience, Alios, and AIT; Kathryn M. Edwards has been funded by the US Centers for Disease Control to assess wheezing after live attenuated influenza vaccines in children. She has also been funded by Novartis to conduct a vaccine study of Group B streptococcal vaccines in pregnant women, and her institution receives funding from Novartis for her participation in a DSMB for an influenza vaccine efficacy trial. Paul Turner is in receipt of a Clinician Scientist award funded by the Medical Research Council (MR/K010468/1) and has received research support from the Department of Health through the Policy Research Programme (National Vaccine Evaluation Consortium, 039/0031) and a NIHR comprehensive Biomedical Research Centre award to Imperial College London Healthcare NHS Trust. All other authors have no conflicts of interest to disclose.
- Adverse event
- Case definition